Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic HBV (Monarch)

Registry ID

EUCTR2015-005499-46

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE2

Sponsor

Arrowhead Pharmaceuticals, Inc.

Start date

2016-06-24

Completion date

2016-11-30

Last update

2026-08-16

Conditions

• Chronic Hepatitis B Virus (HBV) Infection

Summary

To determine the percentage of chronic HBV patients achieving a 1-log reduction in HBsAg compared to baseline (mean of pre-dose values) at Week 60 after completion of 48 weeks of ARC-520

Locations

• , , Bulgarian Drug Agency

Related clinical trials

• A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)
• New HBV Infection Biomarkers: Clinical Characterization and Impact on Management
• Non-Invasive Model for Fibrosis Regression in HBV Patients

View on source registry